Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Georgios Papadakis
- Target Recruit Count
- 150
- Registration Number
- NCT05586802
- Locations
- 🇨🇭
Service of Endocrinology, Diabetes & Metabolism, Lausanne, Switzerland
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 500
- Registration Number
- NCT05579249
- Locations
- 🇺🇸
Nutrition Research Centre, Loma Linda, California, United States
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3400
- Registration Number
- NCT05567796
- Locations
- 🇦🇺
Momentum Clinical Research Darlinghurst, Darlinghurst, New South Wales, Australia
🇮🇹Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
🇺🇸Univ of Alabama Birmingham, Birmingham, Alabama, United States
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 307
- Registration Number
- NCT05564117
- Locations
- 🇺🇸
Washington Cntr Weight Mgmt, Arlington, Virginia, United States
🇩🇪Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz, Lingen, Germany
🇵🇱Centrum Zdrowia Metabolicznego, Poznan, Wielkopolskie Voivodeship, Poland
ADJUnct Semaglutide Treatment in Type 1 Diabetes
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Viral N. Shah
- Target Recruit Count
- 115
- Registration Number
- NCT05537233
- Locations
- 🇺🇸
Iowa Diabetes Research Center, West Des Moines, Iowa, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Harold Schnitzer Diabetes Health Center, Portland, Oregon, United States
Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 100
- Registration Number
- NCT05533632
- Locations
- 🇨🇱
Hospital San Juan de Dios_Santiago, Región Metropolitana, Santiago, Región Metropolitana, Chile
🇨🇱Hospital Padre Hurtado, Santiago, Región Metropolitana, Chile
🇨🇱Servicios Médicos Godoy Limitada, Santiago, Región Metropolitana, Chile
Effects of Semaglutide on Nicotine Intake
- Conditions
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 24
- Registration Number
- NCT05530577
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
Semaglutide for Alcohol Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 48
- Registration Number
- NCT05520775
- Locations
- 🇺🇸
UNC-Chapel Hill, Chapel Hill, North Carolina, United States
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
- Conditions
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 568
- Registration Number
- NCT05514535
- Locations
- 🇺🇸
Valley Research, Fresno, California, United States
🇺🇸First Valley Medical Group, Lancaster, California, United States
🇺🇸Loma Linda Univ Hlth Cr Endo, Loma Linda, California, United States
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT05498610
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.